ICML 2023 | Venetoclax, lenalidomide + rituximab: a chemotherapy-free regimen for previously untreated MCL
In this video, Alexey Danilov, MD, PhD, City of Hope, Duarte, CA, discusses novel treatments emerging in the field of mantle cell lymphoma (MCL). Prof. Danilov initially comments on the use of BTK inhibitors in the relapsed and frontline settings, before sharing the findings from a trial investigating the combination of venetoclax, lenalidomide and rituximab in patients with previously untreated MCL (NCT03523975). In this trial, patient response rates to the chemotherapy-free combination were high, and the regimen was well tolerated. Patients with TP53 gene aberrations had poorer outcomes, and Prof. Danilov highlights the unmet need in these patients with both current and novel treatments. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
A.V.D. has received consulting fees from Abbvie, AstraZeneca, Bayer Oncology, BeiGene, Bristol Meyers Squibb, Genentech, GenMab, Incyte, Lilly Oncology, Nurix, Oncovalent, Pharmacyclics and TG Therapeutics and has ongoing research funding from Abbvie, AstraZeneca, Bayer Oncology, Bristol Meyers Squibb, Cyclacel, MEI Pharma, Nurix, TG Therapeutics and Takeda Oncology.
